Jane van Heteren

Jane van Heteren is an experienced scientist specializing in gene therapy and molecular biology. Currently serving as an Associate Principal Scientist at Alnylam Pharmaceuticals since June 2022, Jane's prior roles include Senior Associate Scientist II at bluebird bio, where non-clinical in vivo studies were conducted for lentivirus-mediated gene therapy, and Senior Research Associate at Vertex Pharmaceuticals, focusing on CRISPR-Cas9 applications for muscular dystrophy. Jane's expertise encompasses in vivo experiment design, AAV and gene therapy development, and techniques like ELISA and ddPCR. With a Master of Science in Molecular Pharmacology from Vrije Universiteit Amsterdam and a background in geology, Jane's career spans multiple prominent biotechnology firms and academic institutions, contributing to various innovative therapeutic approaches.